Phase 3 Trial Shows Positive Results for Oral Acne Drug Denifanstat
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
The treatment is the first short-duration facial injectable available in the region for the temporary improvement of lines between the eyebrows.